not all would have the skills to evaluate the various options critically. It is well recognized that there are variations in clinical practice, both within communities and between communities. While variations in practice do not necessarily and invariably mean poor practice by some, they certainly do raise the question and attendant concern about whether there is delivery of appropriate care and the best use of resources. There is no doubt that a major force driving guideline development has been concern over escalating health care costs and a desire to contain them, obtaining the most benefit for the least dollars. Finally, there is pressure for greater public accountability and increased public involvement in decision-making. Guidelines are one tool for making care more consistent and closing the gap between what clinicians do and what the evidence supports (15) . Cost, quality and unnecessary care are all at issue (19) . The premise is that guidelines will facilitate more consistently effective and efficient medical care, and ultimately lead to improved outcomes for patients (22) . Given the different reasons for guidelines, it is not surprising that they come from a number of different sources: local groups of physicians, specialty and subspecialty societies, governmental and nongovernmental organizations, and third party payers, not infrequently with pharmaceutical industry financial support.
The American guidelines initiative gained a foothold in late 1989 with the creation of the Agency for Health Care Policy and Research (AHCPR). As part of its broad responsibilities for supporting research, data development and other activities to enhance the quality, appropriateness and effectiveness of health care services, one of their functions was to develop, disseminate and evaluate practice guidelines (23) . At its request, the Institute of Medicine (IOM), Washington, DC appointed a committee to advise AHCPR on how to approach this. The result was two publications that provided guidance on definitions and key attributes of guidelines as well as their development, implementation and use (23, 24) . In Canada, the Canadian Medical Association established a quality of care committee to spearhead a national initiative on quality of care in 1990 (25) (18, 19, 21, 22) . Elsewhere, guidelines have either been in existence for a number of years (United Kingdom, Australia) or have recently been developed (the Netherlands, Finland, Sweden, France, Germany, Italy, Spain and New Zealand) (15) .
What exactly are clinical practice guidelines? The IOM has defined them as systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances (23) . It believes that such guidelines can serve as useful tools for many desirable changes, from improving the quality of clinical care (and its measurement) to reducing the financial cost of inappropriate, unnecessary or dangerous care (24) . Clinical practice guidelines gather, evaluate and combine evidence, and attempt to address all the issues relevant to a clinical decision and all the values that may sway a clinical recommendation (26) . Guidelines may find several roles: quality assurance, enhancement of access to care, cost control, patient empowerment, professional autonomy and medical liability, and physician education (18) .
Woolf et al (15) identified a number of potential benefits to patients, health care professionals and the health care system from the application of clinical practice guidelines. For patients, the potential benefits include improved outcomes through promotion of effective interventions, avoidance of ineffective ones, consistency of care and education. Clinical guidelines may indirectly benefit patients by influencing public policy, resource distribution and the research agenda toward initiatives that improve health outcomes. The potential benefits for health care professionals are the improved quality of decisions deriving from recommendations based on a critical review of the evidence, support of quality improvement activities and identifying gaps in knowledge to be pursued through research. These benefits to patients and health care workers will, in turn, benefit the health care system.
Like many things, however, guidelines may be a two-edged sword and should not be viewed as the panacea for a troubled health care system. They have their limitations and potential harms (15, 27, 28) . For many health problems, the scientific evidence supporting various treatment options may be limited, misleading or even nonexistent. It is often necessary to consider various types of evidence, ranging from large, randomized controlled trials to expert opinion. When the evidence is incomplete, there will be legitimate variation in the inferences drawn from it (19) . Recommendations based solely on clinical judgment and experience are more likely to be susceptible to bias and self-interest (26, 28) . Even where good evidence exists, practitioners may interpret it differently, perhaps related to their specialty or subspecialty biases. Additionally, specialist bodies, third party payers or other interest groups may have a vested interest in certain management options (19) . Individual biases may be better balanced in multidisciplinary groups, and such balance may produce more valid guidelines (26, 28) . In view of the differing levels of evidence, methods for developing guidelines and the recommendations coming from them may also vary widely, even in a single area, if the developers draw on different studies and have different strategies for using and ranking expert opinion. A quality-of-evidence scale can be included with the guidance to rate different categories of evidence and the methods that were used, as well as a strength of evidence scale (26 
Validity
The most critical attribute. If followed, a valid practice guideline will lead to the health and cost outcomes projected for it Will consider items outlined in Table 2 Reliability and Given the same evidence and methods reproducibility for guideline development, another set of experts would produce essentially the same statements and given the same clinical circumstances, guidelines are interpreted and applied consistently
Clinical applicability As inclusive of defined populations as evidence and expert judgment permit, and explicitly stating the populations to which they apply
Clinical flexibility
The specifically known or generally expected exceptions identified Clarity Unambiguous language used; terms defined precisely; logical and easy-tofollow presentation use
Multidisciplinary process Includes participation by representatives of key affected groups through: serving on developing panels, providing evidence, reviewing draft guidelines
Scheduled review
Include statements about when the guidelines should be reviewed to determine whether revisions are warranted Documentation Procedures followed, participants, evidence used, assumptions and rationales accepted, and analytic methods used different outcomes by patients, nor actual health care priorities and needs. Additionally, patient needs may not be the only priority considered in making recommendations. As a result, doctors may be faced with a number of guidelines on a single topic, potentially with conflicting and/or faulty recommendations. In the extreme, this could result in guidelines that are wrong or at least wrong for the individual patient. It is important to remember that guideline recommendations have to be evaluated critically by the user and may need to be set aside by individual patient considerations and choices (19) . Apart from the potential for being incorrect, conflicting recommendations from (and within) different groups can lead to irritation, confusion and mistrust of guidelines in general. Even in the absence of conflict, multiple guidelines raise important questions about duplication of effort and wasted resources. The potential harm of clinical practice guidelines to health care professionals is if guidelines provided inaccurate information and advice leading to ineffective, harmful or wasteful interventions; were conflicting; were difficult or time consuming to use; were used to judge an individual physician's practice unfairly; or discouraged the research agenda by declaring efficacy, or lack thereof, of an intervention (15) . Guidelines have the potential to increase utilization (which may be justified and result in worthwhile and beneficial outcomes), divert resources to other areas, and if wrong, compromise efficiency and waste resources. This is not to say that the clinical practice guideline effort should be left behind and move exclusively to other initiatives to improve the quality of care. Rather, increased effort should be put into developing guidelines according to standardized methodologies and into their evaluation. Agencies and groups taking responsibility for guideline development should have an overall plan that includes setting priorities and design, testing, implementation, evaluation and revision. An explicit description of the methodology used to develop the guideline is crucial for the user to assess its value, and understand why and where it may differ from other guidelines on that topic (29) . Guidelines should receive external review to insure content validity, clarity and applicability, with reviewers covering three areas: content expertise, systematic reviews and/or guideline development and use (28) . Practice guidelines deserve the same degree of rigorous consideration that the evidence on which they are based received (19) .
If practice guidelines are to facilitate high quality care, they must be developed and prescribed carefully (22) . The IOM has identified eight attributes of practice guidelines (Table 1) , all linked by credibility (with practitioners, patients, payers and policy makers) and accountability (23) . The key to accountability is disclosure and meticulous documentation of the procedures, participants, evidence, assumptions, rationales and analytic methods used in forming the guideline. If these are not included, the reader may be suspicious that the steps were not performed systematically, and then he or she is left unable to evaluate the guidelines and their suitability for his or her practice (26,29,30) . The most important attribute is validity. Elements needed to allow the determination of validity are a description of the options and outcomes considered, the literature reviewed, evidence for the outcomes, estimates of the effect of the guideline (benefits, harms and costs) on the outcomes, methods used to make the estimates and patient preferences for the outcomes (26, 29, 31) . Hayward et al (27) have recommended an abstract format (Table 2) for authors to use with their guidelines to assist the user in judging their validity. More consistent reporting of guideline development methods is needed to make the guideline literature more accessible to and useful for prospective guideline users (32) . Explanations should be provided for any conflict or inconsistency between the guideline in question and those developed by others. This documentation may help the user to judge where differences are arising: the interpretation of the evidence, rationale for the guideline, targets of the guideline, objectives of the guideline, value judgments, or care in developing the guidelines (22, 23, 31) .
What do physicians think about clinical practice guidelines? It seems to be a lukewarm relationship at best. The results of a survey of 2600 members of the American College of Physicians were published in 1994 (20) . The survey's purpose was to assess familiarity with and confidence in clinical practice guidelines. There was a 60% response rate. The following views were held: 65% thought that guidelines would improve the quality of care, 43% believed that they would increase health care costs, 68% felt that they would be used to discipline physicians, 34% thought that they would make practice less satisfying, and 64% and 67%, respectively, believed that they were good educational tools and convenient sources of advice. Of interest, and perhaps reflecting an inherent suspicion of third party payers, was the finding that 6% and 82%, respectively, gave high ratings to the same guidelines for diagnostic testing developed by Blue Cross/Blue Shield, an insurance company, and the American College of Physicians. Also not surprising was that subspecialists had the greatest confidence in and more familiarity with guidelines developed by their own subspecialty organizations. Finally, while most respondents reported that clinical practice guidelines had some effect on their decisionmaking, fewer than 20% rated it as major. Members of the Canadian Infectious Disease Society (CIDS) in attendance at CIDS Day 1999 offered their views on clinical practice guidelines (Table 3 ) (personal communication, L Johnston). Most (40%) felt that guidelines should be developed by national medical and subspecialty societies while others believed that they should be developed by individual facilities to meet local needs (24%), an independent institution with expertise in guideline development (24%) or government-funded multidisciplinary groups (12%).
In the end, clinical practice guidelines are only one option for improving the quality of care (32). Woolf et al (15) has suggested that they make sense when practitioners are unclear about appropriate practice and when scientific evidence can provide an answer. When clinicians already know the information, the task needs to shift to identify ways to change behaviour. Implementation is as critical as developing the guideline (32) . Factors influencing acceptability include representation of the user group(s) on the developing body and perceived ownership of the opinion (19) . This underlines the importance of one of the attributes noted by the IOM -a multidisciplinary process. We, as clinicians, must critically evaluate clinical practice guidelines before applying them to our patients. As members of a subspecialty society, we should support the development, implementation and evaluation of practice guidelines that fulfill the attributes outlined by the IOM and address high priority health care needs. In the modern world of health care, it seems that society is often many years behind in dealing with the bioethical dilemmas that arise as a result of new technologies, treatments and diseases or illnesses. Even though the human immunodeficiency virus (HIV) has been with us for over two decades, the ethics of the pandemic continue to pose interesting challenges to everyone involved in the care of individuals infected with and affected by this retrovirus.
HIV and AIDS Testing, Screening, and Confidentiality is a timely and important book. It examines the issues of HIV testing, screening and confidentiality, primarily from the European perspective. It also includes references to and cases from the past, but with a view to the future. There are several authors, including ethicists, philosophers, physicians, lawyers, researchers and psychologists, who contribute to the in-depth views represented in the book. While there is no Canadian content, one chapter examines the subject from a critical, legal, American perspective. The cases and arguments used to illustrate subjects such as 'Individual responsibility for health' and 'Can health care workers care for their patients and be third-party interests?' are presented clearly and with passion. Some questions are answered, and others are raised.
A book written by the Pan American Health Organization in 1992 titled Ethics and Law in the Study of AIDS by Fuenzalida-Puelma et al addresses similar issues; however, it does so from a Pan American perspective.
Although HIV and AIDS Testing, Screening, and Confidentiality is well referenced, one criticism is that many of the references are dated before 1995. However, the writing is consistent, and the editors have done a good job of keeping the authors on track with their respective subject matters. There are no pictures or graphic illustrations.
Obviously, HIV and AIDS Testing, Screening, and Confidentiality will be of interest to those involved with bioethics, but it is also suitable reading and a resource for philosophers, lawyers, social workers, legislators or policy makers, HIV advocates, researchers, health care trainees, and health care professionals. It would be a valuable reference book for libraries.
Anne Russell RN According to Canada's Laboratory Centre for Disease Control, regular screening is imperative in controlling the spread of these sexually transmitted diseases. In the United States, the recent Healthplan Employee Data Indicator Set Measure cites a 66% reduction in pelvic inflammatory disease within one year of screening in a representative sample of sexually active females aged 15 to 25 years.
NEW, FIRST-LINE TREATMENT OF SEXUALLY TRANSMITTED DISEASE/HUMAN PAPILLOMA VIRUS ANOGENITAL WARTS EXPLAINED ON WEB PAGE
Stiefel Laboratories' product Web site (www.wartec.com) contains a comprehensive explanation of anogenital warts caused by the human papillomavirus (HPV). The site also details the advantages of podophyllotoxin, the active ingredient in WARTEC (Stiefel Canada Inc, Canada), for home therapy, as endorsed by the European Course on HPV Associated Pathology.
The WARTEC Web site is targeted at the general public, health care professional and the media. The public section is available in eight languages. Health care professionals are able to access the WARTEC monograph and summary of product characteristics, as well as a diagnosis and patient management question and answer section (in English) with Associate Professor G Von Krogh. The media section contains press release archives, fact sheets and a glossary. 
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ERRATA
In In the paper, "An algorithm for the management of acute bacterial cellulitis" (Can J Infect Dis Vol 11[Suppl D]:11D-14D), the dose of oral ciprofloxacin in Table 1 for cat bite is written as 100 mg bid. It should be 500 mg bid. The error is regretted.
CHLAMYDIA AND GONORRHEA NOW SIMPLE TO DIAGNOSE IN CANADA
Chlamydia and gonorrhea infections affect 11.3% of the Canadian adult population, and rates of infection continue to soar. New cases of these bacterial infections are approximately four times more common than new cases of genital herpes or genital warts combined.
According to Health Canada's Surveillance Report, the morbidity of chlamydia and gonorrhea, and its associated costs make these infections an important health issue. Both infections are nationally reportable diseases whose incidence rates are tracked annually.
The disproportionally high incidence of chlamydia in young females in Canada is cause for great concern, especially when considering estimates that approximately 70% of chlamydia cases in women are asymptomatic and, as a result, largely undiagnosed. Untreated chlamydia and gonorrhea infections in females can lead to serious and costly health complications, including pelvic inflammatory disease, ectopic pregnancies and/or infertility. Once diagnosed, chlamydia and gonorrhea are easily treatable with antibiotics.
Traditional invasive swabs tests have deterred many individuals from screening. A new screening test by Becton Dickinson requires a simple urine sample and is considered to be more sensitive than conventional tests.
According to Canada's Laboratory Centre for Disease Control, regular screening is imperative in controlling the spread of these sexually transmitted diseases. In the United States, the recent Healthplan Employee Data Indicator Set Measure cites a 66% reduction in pelvic inflammatory disease within one year of screening in a representative sample of sexually active females aged 15 to 25 years.
NEW, FIRST-LINE TREATMENT OF SEXUALLY TRANSMITTED DISEASE/HUMAN PAPILLOMA VIRUS ANOGENITAL WARTS EXPLAINED ON WEB PAGE
